Physician profile
Sherri Eagle
NPI 1831896109
$493.88
in general payments reported to CMS, 2019-2025
13 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $151 · 2024: $146 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.80 | 2023-2024 | Lifevest |
| Gilead Sciences, INC. | $81.87 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $54.14 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $45.14 | 2023 | Verquvo |
| Teva Pharmaceuticals USA, INC. | $37.99 | 2025 | Ajovy, Austedo Xr |
| Ani Pharmaceuticals, INC. | $29.55 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $28.89 | 2024-2025 | Glassia |
| Janssen Pharmaceuticals, INC | $23.43 | 2023 | Xarelto |
| Abbvie INC. | $22.27 | 2024 | |
| Pfizer INC. | $21.87 | 2025 | |
| Mylan Specialty L.P. | $20.96 | 2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $20.86 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $20.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherri Eagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.